Exelixis to Release Second Quarter 2015 Financial Results on Tuesday, August 11, 2015
Get Alerts EXEL Hot Sheet
Join SI Premium – FREE
- Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m. PDT -
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2015 financial results will be released on Tuesday, August 11, 2015 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company’s website.
To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under Investors & Media. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 855-793-2457 (domestic) or 631-485-4921 (international) and provide the conference call passcode 94776699 to join by phone.
A telephone replay will be available until 11:59 p.m. EDT on August 13, 2015. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 94776699. A webcast replay will also be archived on www.exelixis.com for one year.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech, Inc. (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company's web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150728006806/en/
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor
Relations and Corporate Communications
[email protected]
Source: Exelixis, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Highwoods Properties (HIW) Tops Q1 EPS by 6c, provides guidance
- Trustmark Corp (TRMK) Tops Q1 EPS by 7c
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!